| 한국 시신경척수염 환자에서 1차 치료제로서의 Rituximab 비용 효율 연구 |
|
현재원, 장현민, 박정미a, 이민영, 김수현, 김호진 |
국립암센터 신경과
a경기웰니스요양병원 재활의학과 |
| Cost Effectiveness of First-Line Rituximab in Koreans with Neuromyelitis Optica Spectrum Disorder |
|
Jae-Won Hyun, Hyunmin Jang, Jeongmi Parka, Min Young Lee, Su-Hyun Kim, Ho Jin Kim |
Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea;
aDepartment of rehabilitation, Gyeonggi Wellness Geriatric Hospital, Yangju, Korea |
|
|
| Abstract |
|
"Background: This study aimed to evaluate the cost-effectiveness of first-line rituximab therapy in individuals with neuromyelitis optica spectrum disorder (NMOSD) in Korea.Methods: This study enrolled 42 participants with NMOSD from the clinic of neuroimmunological diseases of the central nervous system at National Cancer Center. Of these participants, 21 were treated with first-line rituximab therapy (first-line rituximab group) and 21 were treated with second-line rituximab after switching from azathioprine therapy (second-line rituximab group). Data on direct medical resource consumption, including hospitalizations for acute attack management, clinic visits to physicians, examinations, medication use, and rehabilitation, were collected through a review of medical records and structured interviews of participants. The mean annual direct medical cost per person for the 5 years after maintenance immunosuppressive therapy was investigated and compared between the two groups.Results: The mean total annual direct medical cost per person was 8.9 million won. The mean annual direct medical cost per person was 1.8 times higher in the second-line rituximab group than in the first-line rituximab group (10.0 vs. 5.5 million won; p=0.028). The mean annual direct medical cost per person during azathioprine therapy (14.8 million won) in the second-line rituximab group was significantly higher than that in the first-line rituximab group (p=0.015).Conclusions: Even without considering indirect costs, NMOSD has a high economic burden in Korea. These results suggest that first-line rituximab therapy is more cost-effective than first-line azathioprine therapy in individuals with NMOSD.Journal of Multiple Sclerosis and Neuroimmunology 11(2):53-58, 2020" |
| Key Words:
Key Words: Neuromyelitis optica spectrum disorder, Cost, Azathioprine, Rituximab |
|
PDF Links
Download Citation
